Capital Flow Monitor · Sponsors · CIK 2087033
OrbiMed Private Investments X, LP
601 LEXINGTON AVENUE, NEW YORK, NY, 10022 · 212-739-6400
Pooled Investment Fund / Private Equity Fund · Limited Partnership· inc. DELAWARE true 2025
Fit score
—
Offering
$1.75B
Sold
$1.67B
% sold
95.4%
Investors
119
Min investment
$0
Exemption
506(b)
Filing history
| Filed | Form | Rule | Offering | Sold | % sold | Investors | |
|---|---|---|---|---|---|---|---|
| 2026-04-30 | D/A ·current | 506(b) | $1.75B | $1.67B | 95.4% | 119 | EDGAR ↗ |
| 2025-09-29 | D | 506(b) | $1.75B | $0 | 0.0% | 0 | EDGAR ↗ |
Related persons
Executive officers, directors and promoters, as filed.
- N/A OrbiMed Capital GP X, LP — Executive Officer, New York, NY
- N/A OrbiMed Capital GP X LLC — Executive Officer, New York, NY
- N/A OrbiMed Advisors LLC — Executive Officer, New York, NY
- Mona Ashiya — Executive Officer, New York, NY
- David P. Bonita — Executive Officer, New York, NY
- Sven H. Borho — Executive Officer, New York, NY
- Carl L. Gordon — Executive Officer, New York, NY
- Geoffrey C. Hsu — Executive Officer, New York, NY
- W. Carter Neild — Executive Officer, New York, NY
- Matthew S. Rizzo — Executive Officer, New York, NY
- C. Scotland Stevens — Executive Officer, New York, NY
- Peter A. Thompson — Executive Officer, New York, NY
Placement agents
- Merrill Lynch, Pierce Fenner & Smith Incorporated · 17 RE raises
- Ubs Financial Services Inc. · 13 RE raises
- Ubs Switzerland Ag · 0 RE raises
Source: SEC EDGAR Form D. Self-reported by the issuer. Not investment advice.